Inavolisib is an oral targeted therapy classified as a PI3K alpha-selective inhibitor, utilized in the treatment of specific cancers such as HR-positive, HER2-negative breast cancer. To support rigorous… Read more
Inavolisib is an oral targeted therapy classified as a PI3K alpha-selective inhibitor, utilized in the treatment of specific cancers such as HR-positive, HER2-negative breast cancer. To support rigorous analytical testing and quality control throughout the drug development lifecycle, this category provides high-quality reference standards essential for method validation and impurity profiling. Laboratories rely on these materials to identify and quantify potential byproducts, including process-related degradation products and N-nitroso derivatives, ensuring compliance with strict regulatory standards. The inclusion of stable isotope-labelled compounds, such as deuterium-labelled variants, facilitates precise quantification in complex biological matrices via mass spectrometry-based assays. By providing access to characterized API standards, degradation products, and labelled internal standards, this collection enables accurate routine analysis and stability studies for pharmaceutical formulations containing this potent kinase inhibitor.